Acquired Multi-Drug Resistance

$110,203P01FY2013CANIH

University Of Washington, Seattle WA

Investigators

Linked publications, trials & patents

Paper 34425871 Paper 34186431 Paper 32591490 Paper 32374053 Paper 32331709 Paper 32280746 Paper 31676728 Paper 30796683 Paper 30100079 Paper 29449411 Paper 29201941 Paper 28191877 Paper 28187357 Paper 27990685 Paper 27342400 Paper 26912434 Paper 26850484 Paper 26834106 Paper 26807443 Paper 26493206 Paper 26294301 Paper 26112020 Paper 25795318 Paper 25737423 Paper 25704387 Paper 25656434 Paper 25638395 Paper 25540239 Paper 25537988 Paper 25392718 Paper 24868025 Paper 24861984 Paper 24770914 Paper 24170452 Paper 23940302 Paper 23359659 Paper 23133794 Paper 23087780 Paper 22985987 Paper 22898682 Paper 22819579 Paper 22560972 Paper 22423895 Paper 22052127 Paper 21982568 Paper 21903739 Paper 21872957 Paper 21750198 Paper 21562060 Paper 21421714 Paper 21364034 Paper 21285676 Paper 21031518 Paper 20956476 Paper 20720049 Paper 20460489 Paper 20237040 Paper 20161481 Paper 20011618 Paper 19830267 Paper 19709971 Paper 19706819 Paper 19687472 Paper 19617341 Paper 19372493 Paper 19366800 Paper 19326172 Paper 19293766 Paper 19289422 Paper 19091885 Paper 19010830 Paper 18790395 Paper 18627198 Paper 18626006 Paper 18544441 Paper 18543042 Paper 18523071 Paper 18523070 Paper 18451225 Paper 18287268 Paper 18180228 Paper 18055860 Paper 17921038 Paper 17920354 Paper 17892371 Paper 17649907 Paper 17575208 Paper 17504870 Paper 17368207 Paper 17268819 Paper 17204692 Paper 17153406 Paper 17118889 Paper 17043737 Paper 17020961 Paper 17015896 Trial NCT03649880 Trial NCT03613259 Trial NCT02167204 Trial NCT02149173

Abstract

Anthracycline based therapy is a mainstay for many patients with solid tumor cancers. However, many of these tumors have variable levels of multiple drug resistance (MDR) transporters that reduce treatment effectiveness. The P-glycoprotein (Pgp) system specifically acts as a membrane pump to exclude anthracyclines and other common chemo therapeutics from intracellular accumulation. The activity of this transporter system can be up-regulated after exposure to anthracycline treatment and this is a suspected variable in treatment resistance and failure. In this project, we will quantify Pgp activity using a known transporter substrate, r^C]-verapamil, for tumor imaging. The uptake kinetics of this imaging agent can be used to quantify tissue Pgp activity when the tumor area under the curve from 0 to 20 min (AUC0.20) is normalized to the same AUC for blood. Imaging in sarcoma patients showed a range of [C]-verapamil kinetics in tumors. Patients with several cancer histologies undergoing anthracycline-based treatment protocols will be studied before treatment and after exposure to chemotherapy to measure the extent of acquired MDR. Careful control experiments will be needed for this study. Determine pre-treatment levels of Pgp activity in tumors using [^^C]-verapamil to test the hypothesis that tumors express a wide range of intrinsic multiple drug resistance prior to therapy. Investigate FMISO as a comparison reference for the tumor input function by normalizing the AUC for verapimil to that for FMISO. Determine the changes in tumor Pgp expression after treatment with anthracyclines using f ^C]-verapamil PET to test the hypothesis that certain tumors will show an up-regulation of Pgp transporter activity after treatment with anthracyclines. The extent of acquired MDR may or may not correlate with pre-treatment levels of [''C]-verapamll uptake. Correlate changes in f ^C]-verapamil kinetics with patient survival to test the hypothesis that patients who up-regulate their tumor Pgp activity will have shorter survival. When development of f ^C]-A(jriamycin by Proj 5 is ready for clinical studies (anticipated in yr 3), we will start comparison studies of it with [ C]- verapamil in our cancer patient groups.

View original record on NIH RePORTER →